Compound Screening TRIZ Cases

A mitoferrin-2 inhibitor arrests growth and induces abnormal morphology in cancer cells.

Functionalized recombinant mononucleosomes enable rapid quantification of enzymatic activity via direct fluorescence readouts.

Cross-linked polypeptides inhibit viral fusion by stabilizing alpha-helical structures, addressing inadequate treatment for drug-resistant strains.

DNA microarrays detect differential gene expression in brain regions to identify diagnostic biomarkers, resolving the complexity of genetic analysis systems.

Measuring AI-2 biomarkers in oral fluids enables early periodontal disease diagnosis before significant plaque accumulation occurs.

A tumor-penetrating peptide fused to an antibody heavy chain constant region enables selective accumulation in solid tumors.

Antibodies isolate the 24P4C12 antigen to improve diagnostic accuracy and enable targeted therapy for metastatic prostate cancer.

Targeted antagonists suppress aberrant SCN10a and KCNQ1 activity to alleviate cognitive deficits while minimizing peripheral adverse effects.

Measuring ICAM-1 binding to SRC identifies inhibitors that regulate metastasis and angiogenesis, resolving detection accuracy versus procedural side effects.

Measuring IKZF1, IKZF3, NFE2, and IRF8 protein levels enables early prediction of melanoma metastasis before clinical symptoms appear.

A multi-marker panel isolates long-term hematopoietic stem cells from cord blood samples.

Biomimetic platforms recreate human pulmonary arteriole structure and function using composite microtissues.

Dynamic fluid perfusion applies shear stress to renal organoids, resolving the trade-off between culture simplicity and reliable vascular development.

Antisense oligonucleotides degrade accumulated Alu RNA in retinal pigment epithelium cells, preventing geographic atrophy progression.

Compounds bind the Ras Switch 2 pocket to inhibit oncogenic activity.

Arrestin recruitment enables luminescent detection of receptor modification without labeling the target protein.

Cell-free translation system constructs non-standard peptide libraries incorporating N-methyl amino acids for targeted screening.

Small molecules disrupt the TONSL-H4 tail interaction to compromise homologous recombination repair and sensitize cancer cells to chemotherapy.

Detecting specific p53 isoforms resolves diagnostic specificity issues by distinguishing metastatic potential across heterogeneous patient populations.

BL-8040 upregulates miR-15a and miR-16-1 to downregulate BCL-2, overcoming resistance to BCL-2 antagonists.

Inhibiting the glycine cleavage system reduces tumor cell viability and proliferation.

CD89 surface markers distinguish infected lymphocytes from healthy cells, enabling precise elimination of persistent viral reservoirs.

Administering a ganglioside molecular mimic neutralizes specific pathogenic antibodies, avoiding invasive plasmapheresis side effects.

Targeting the catalytically active JH2 domain of JAK proteins enables precise modulation of kinase activity through specific assay development.

Non-human animals with humanized immunoglobulin loci drive B cell clonal selection to produce broadly neutralizing antibodies.

Automated GPMV analysis detects phase separation changes to find specific modulators, avoiding pleiotropic effects from non-specific cholesterol depletion.

Fusion proteins combine arrestin polypeptides with ubiquitin-like proteins to resolve detection precision limits in GPCR signaling studies.

Engineered intact antibodies bypass cell membrane barriers to inhibit intracellular activated RAS, enabling targeted cancer therapy without cytotoxicity.

A polypeptide targets the CD95 receptor intracellular region to block calcium signaling pathways.

Whole blood lysosomal flux assessment uses chloroquine inhibition to measure autophagic markers, enabling direct clinical evaluation of human samples.

Detecting phosphorylated p53 binding identifies anti-senescence compounds that induce apoptosis in senescent cells.

Fluorescently labeled nanoparticles cross cell membranes to detect drug-resistant tumor cells, bypassing complex synthesis processes.

Modified peptide nucleic acid agents enhance cellular delivery through cationic and hydrophobic moieties.

AHR agonists activate the aryl hydrocarbon receptor system to overcome delayed SSRI response rates in major depressive disorder.

Magnetic beads transport reagents through a rehydrated aqueous two-phase system, eliminating gel substrate interference with cell interactions.

Adaptive mutations enable hepatitis C virus replication in cell culture, resolving genotype coverage limits.

Substituting non-natural amino acids at anchor positions in peptide derivatives to enhance MHC class I binding affinity.

Segmented in vitro skin models replicate infant pathophysiology to identify effective emollients despite evaluation system complexity.

Specific amino acid substitutions in histone H3.3 enable targeted molecular diagnostics that address ineffective pediatric glioblastoma treatments.

Peptide compounds mimic ACE2 structural determinants to block viral entry, accelerating treatment development through preliminary action and segmentation.

Agonistic antibodies maintain receptor occupancy below 80% to reduce toxicity while enhancing anti-tumor activity.

A cell culture-based assay uses immortalized valve interstitial cells to identify compounds inhibiting osteogenic differentiation.

ATP-γ-S replaces ATP to eliminate contaminating ATPase interference, enabling accurate luminescence-based kinase inhibitor screening.

Kinetic models guide mechanism-based sirtuin activator design.

Stem cell marker detection resolves heterogeneous population identification challenges in human iPS cell reprogramming.

A GFP-beta-lactamase fusion reporter enables quantitative mutation detection via dual fluorescence and antibiotic resistance signals.

PTCH1-luciferase reporter cassette in immortalized keratinocytes resolves unstable expression and low sensitivity during basal cell carcinoma drug screening.